. In addition, it is also thought to function as a regulator of p53 function. This stems from evidence that the MDM2 protein forms oligomeric complexes with the p53 protein in vivo and in vitro (Momand et al., 1992; Oliner et al., 1992) and when experimentally overexpressed inhibits the transactivating capability of p53 (Momand et al., 1992) . This inhibition is thought to result from the MDM2 protein binding directly to the acidic activation domain of p53, concealing it from the transcriptional machinery (Oliner et al., 1993) . Apart from its role as a p53 regulator, MDM2 also has oncogenic properties, as evident from transfection studies in which MDM2 overexpression was found to increase the tumorigenic potential of NIH3T3 and Rat2 cells (Fakharzadeh et al., 1991) and to overcome wild-type p53 suppression of transformed cell growth (Finlay, 1993 Following hybridisation with a [a-32PJdCLTP-labelled human MDM2 cDNA probe (C14-2), the membranes were exposed to intensifying screens for 2-10 days at -70°C. The blots were subsequently reprobed with the pDCCl.65 probe, which
MDM2 is an evolutionarily conserved gene (Fakharzadeh et al., 1991) which was originally identified as a highly amplified gene present on double minutes in a spontaneously trans- formed tumorigenic derivative of a Balb/c cell line called 3T3DM (Cahilly-Snyder et al., 1987) . Subsequently, Oliner et al. (1992) cloned the human MDM2 gene and localised it to chromosome 12ql 3-14. Analysis of the predicted amino acid sequence of the MDM2 protein suggests that it may be a DNA-binding protein or transcription factor (Fakharzadeh et al., 1991; Oliner et al., 1992) . In addition, it is also thought to function as a regulator of p53 function. This stems from evidence that the MDM2 protein forms oligomeric complexes with the p53 protein in vivo and in vitro (Momand et al., 1992; Oliner et al., 1992) and when experimentally overexpressed inhibits the transactivating capability of p53 (Momand et al., 1992) . This inhibition is thought to result from the MDM2 protein binding directly to the acidic activation domain of p53, concealing it from the transcriptional machinery (Oliner et al., 1993) . Apart from its role as a p53 regulator, MDM2 also has oncogenic properties, as evident from transfection studies in which MDM2 overexpression was found to increase the tumorigenic potential of NIH3T3 and Rat2 cells (Fakharzadeh et al., 1991) and to overcome wild-type p53 suppression of transformed cell growth (Finlay, 1993) . Therefore, its role in tumorigenesis and its detectable alteration in tumour samples is of clinical interest. At the DNA level, a number of groups have examined MDM2 amplification in non-epithelial tumours. Of these, MDM2 amplification ranging from 4-to 70-fold has been reported in 14% (4/28) of osteogenic sarcomas (Ladanyi et al., 1993) , 10% of primary brain tumours (15/157) (Reifenberger et al., 1993) and up to 36% (17/47) of soft-tissue sarcomas (Oliner et al., 1992; Leach et al., 1993a) , with no apparent amplification in Ewing tumours (Kovar et al., 1993) of myelodysplastic syndrome (Preudhomme et al., 1993) , astrocytomas (Rubio et al., 1993) or leukaemia (Bueso-Ramos et al., 1993) . With regard to the epithelial malignancies, none of the gastrointestinal tumours (Oliner et al., 1992) , cervical cancers (Kessis et al., 1993) or breast cell lines (Sheikh et al., 1993) (Fearon et al., 1990) . This probe, which detects fragments of similar size as MDM2-probed EcoRI DNA, was used as a control probe similar to a previous study (Oliner et al., 1992) . Hybridisation conditions were similar to those previously used (Ohner et al., 1992 
Imnmohistochemistry
The MDM2 and p53 proteins were immunohistochemically assessd on air-dried 5 pm formalin-fixed, paraffin-embedded sections using the commercially available IF2 (Oncogene Science) and NCL-p53 D07 (Novacastra Laboratories) mouse monoclonal antibodies respectively. In the case of MDM2, immunoreactivity was not detectable on paraffinembedded sections using IF2 and standard immunohistochemical procedures. Microwaving of the sections before application of the antibody proved successful. Briefly, the sections were placed in a microwaveable trough, submerged in 10 mm citrate buffer (pH 6.01), wrapped in vented clingfllm and incubated for two 5 min periods at maximum power in a domestic microwave (Beling model MW 820T-800W). Following microwaving, the sections were allowed to come to room temperature in the buffer and rinsed in dis- 
MDM2
The p53 antibody (DO7) was used at a 1:50 dilution for I h at room temperature. Comparative studies of frozen sections using this protocol showed good correlation and, therefore, microwave enhancement was not investigated for this antibody. There have been reports, however, that such treatment may enhance staining with this antibody (Gown et al., 1993) . Immunoreactivity for both p53 and MDM2 was demonstrated using the universal labelled streptavidin-biotin (LSAB), horseradish peroxidase (HRP) kit (Dako) according to the manufacturer's instructions. The sections were counterstained in 0.3% methyl green and scored semiquantitatively following scanning of the entire tumour field. Nuclear immunoreactivity for MDM2 and p53 was scored as negative (0%), type I (<10% nuclei positive), type 2 (10-50% nuclei positive) and type 3 (> 50% nuclei positive). The significane of MDM2 nuclear staining with other cinicopathologial features including accumulated p53 status was assessed using the X2-test.
Redsis Amplification
In the present study, frozen tissue was available for Southern blotting analysis in 82/100 of cases. Of these, MDM2 amplification was present in 4% (3/82) ( Figure 1 , blots la and 2a), and these were histologically classified as infiltrating ductal. The corresponding blots showing reprobing with the control probe pDCCl.65 are also shown (Figure 1 , blots lb and 2b respectively). Sample 10 (Figure 1, blot la) , demonstrated the highest gene copy number based on serial dilutional analysis (4-to 6-fold) and was from a patient whose mother died from breast cancer at the age of 48 and whose brother died at 25 from liver cancer with an unknown b P 1 2 3 4 5 6 7 8 9 P (Figure 2a and b respectively), with some weak cytoplasmic staining. Of the 97 samples assayed, 7% (7/97) had type 2 MDM2 nuclear staining [10-50% of tumour nuclei positive (MDM2+) Table I ]. With the exception of one case of ductal carcinoma in situ (DCIS) (histologically typed as cribiform), all the MDM2+ cases were infiltrating ductal carcinomas. None of the tumours had type 3 staining (> 50% nuclei positive). Type 1 and negative staining frequencies are detailed in Table I , as are the frequencies for p53 nuclear accumulation.
Comparing MDM2 amplification with MDM2 and p53 nuclear protein expression, 2/3 MDM2-amplified samples were MDM2+ (type 2 staining) and one was negative (Table  II) . Of the three amplified samples, only one had gross accumulation of p53 (type 2 staining; sample 16). The two remaining amplified tumours consisted of one tumour negative for p53 (sample 19) and one with type 1 staining (<10% nuclear positivity; sample 10) (Table II) . Finally, 95 cases were assayed for both p53 and MDM2 protein expression using immunohistochemistry. Chi-square analysis indicated that MDM2+ status was significantly associated (P = 0.03) with low levels of p53 (negative and type 1 staining; Table  III) , with 6/7 MDM2+ tumours having this p53 profile. Of note is the fact that 5/7 of these MDM2+ tumours had no underlying gene amplification (Table II) This stems from reports of a lack of p53 mutations in exons 5-9 of familial breast cancer patients (Prosser et al., 1991; Warren et al., 1992) , suggesting p53 mutations may not contribute to hereditary breast cancer. Is it possible that MDM2 could play a role in these cases? It is hard to conceive however, how gene amplification could be inherited, and it may be that some other mechanism could predispose to an amplification event. One possibility is that an inherited mutation in a gene responsible for the fidelity of DNA replication, such as MSH2 (Leach et al., 1993b) , could result in genomic instability leading to gene amplification. Microwave-based antigenic unmasking has recently been evaluated by our group (Kelleher et al., 1994) and others, and is a recommended technique for use in paraffin material for detecting a wide range of antigens (Shi et al., 1991; Gown et al., 1993) . The frequency of 7% positive immunostaining for the MDM2 protein is slightly higher than the altered frequency we report at the DNA level and may suggest that mechanisms other than gene amplification can lead to aberrant MDM2 expression, for example oestrogen may modulate MDM2 mRNA expression (Shiekh et al., 1993) .
The fact that one of our amplified samples had no apparent alteration in MDM2 protein expression suggests that in a subset of tumours the amplification event could be driven by a different gene within this chromosomal region. Possible candidate genes are CDK4 or gli, which have been reported to be co-amplified with MDM2 in an osteosarcoma cell line (Khatib et al., 1993) . The 12ql3-14 amplicon may therefore represent a similar situation to that found with the llql3 regional locus in breast carcinomas, in which int-2, although not expressed, is frequently co-amplified with hst-1 and bel-l (cyclinD/PRAD1), with the latter reported to have elevated transcription accompanied by its amplification (Yoshida et al., 1993) .
Looking at MDM2 gene amplification in association with accumulated p53 status, 1/3 amplified MDM2+ tumours demonstrated type 2 p53 nuclear staining (10-50% of tumour nuclei positive). This is similar to a previous study (Reifenberger et al., 1993) in which two MDM2-amplified samples displayed significantly increased levels of p53 mRNA, with one case showing concomitant p53 nuclear expression in the majority of the tumour nuclei as determined using the D07 antibody. The significance of this accumulation in the present study is difficult to interpret without sequence analysis. Firstly, accumulation of p53 in the majority of cases has been shown to be synonymous with the presence of underlying p53 mutations (Singh el al., 1993) . These mutations, however, have not been found in any of the MDM2-amplified samples reported in the literature (Oliner et al., 1992; Reifenberger et al., 1993; Leach et al., 1993a) , suggesting that MDM2 amplification and p53 exonic mutations may be mutually exclusive. Secondly, based on the study of Barnes et al. (1992) reporting on the accumulation of non-mutated, wild type p53 in a familial case, we used the D07 antibody in our study as it detects both the wild-type and mutant p53 forms. Therefore, the accumulation of p53 in this amplified tumour could be of either phenotype and may be due to sequestering by MDM2. Of course, other mechanisms could lead to p53 accumulation resulting from intronic mutations, altered splice patterns, increased protein stability or sequestering by other host proteins. The proposed p53-MDM2 autoregulatory feedback loop (Wu et al., 1993) and the identification of multiple MDM2 proteins and possible MDM2-p53 protein complexes further underlines the complexity of maintaining p53 equilibrium.
In conclusion, our study reports on a frequency of 4% for amplification of the MDM2 gene in human breast cancer and expression of the MDM2 gene product (10-50% nuclei positive) in 7% of samples, and is one of the first reports of such an alteration in epithelial tumours. Based on this frequency, it is unlikely that altered MDM2 will have significant clinical value, but this remains to be determined. The fact that 6/7 MDM2-positive protein samples were p53 negative (P = 0.03) indicates that alterations in MDM2 and p53 may represent alternative pathways in tumorigenesis. Finally, the role of MDM2 alteration in familial/inherited dispositions may be warranted. Abbreviations MDM2, murine double minute 2; cDNA, complementary DNA, DCIS, ductal carcinoma in situ; ER, oestrogen receptor.
